MARKET

LMDX

LMDX

LumiraDx Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.41
+0.18
+1.95%
Closed 16:00 01/14 EST
OPEN
9.23
PREV CLOSE
9.23
HIGH
9.49
LOW
9.02
VOLUME
25.38K
TURNOVER
--
52 WEEK HIGH
11.09
52 WEEK LOW
7.15
MARKET CAP
1.95B
P/E (TTM)
-10.1928
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 2d ago
BRIEF-Lumiradx Lab Analysis Confirms Its Covid-19 Antigen Test Detects The Omicron Variant
reuters.com · 2d ago
LumiraDx's COVID-19 antigen test detects Omicron variant
LumiraDx (NASDAQ:LMDX) announces that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated
Seekingalpha · 2d ago
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live...
PR Newswire · 2d ago
LumiraDx sees FY21 revenue $422M, consensus $376.57M
LumiraDx (LMDX -0.2%) anticipates 2021 FY revenues of $422M compared to $139M Y/Y and Q4 revenues of $119M compared to $101M Y/Y. This expected FY revenue is well above the
Seekingalpha · 5d ago
BRIEF-LumiraDx Has Commenced Shipments In Europe For Its Covid-19 & Flu A/B Microfluidic Antigen Test
reuters.com · 5d ago
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
PR Newswire · 5d ago
BRIEF-Lumiradx CRP Test Achieves CE Marking
reuters.com · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LMDX. Analyze the recent business situations of LumiraDx Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LMDX stock price target is 14.94 with a high estimate of 20.00 and a low estimate of 12.00.
High20.00
Average14.94
Low12.00
Current 9.41
EPS
Actual
Estimate
-0.080.090.250.41
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 27
Institutional Holdings: 8.18M
% Owned: 3.94%
Shares Outstanding: 207.46M
TypeInstitutionsShares
Increased
5
59.57K
New
14
7.22M
Decreased
4
185.51K
Sold Out
48
8.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About LMDX
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.

Webull offers kinds of LumiraDx Ltd stock information, including NASDAQ:LMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMDX stock methods without spending real money on the virtual paper trading platform.